Personalized prediction of antidepressant v. placebo response: Evidence from the EMBARC study

Psychological Medicine

Volumn 49, Issue 7, 2019, Pages 1118-1127

  Webb, Christian A ^a   Trivedi, Madhukar H ^b   Cohen, Zachary D ^c   Dillon, Daniel G ^a   Fournier, Jay C ^d   Goer, Franziska ^a   Fava, Maurizio ^e   McGrath, Patrick J ^f   Weissman, Myrna ^f   Parsey, Ramin ^g   Adams, Phil ^f   Trombello, Joseph M ^b   Cooper, Crystal ^b   Deldin, Patricia ^h   Oquendo, Maria A ^c   McInnis, Melvin G ^h   Huys, Quentin ⁱ   Bruder, Gerard ^f   Kurian, Benji T ^b   Jha, Manish ^b   Derubeis, Robert J ^c   Pizzagalli, Diego A ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^g STONY BROOK UNIVERSITY   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antidepressant; depression; endophenotype; machine learning; placebo; precision medicine; prediction

Indexed keywords

ANTIDEPRESSANT AGENT; SERTRALINE;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; ENDOPHENOTYPE; FEMALE; HUMAN; MACHINE LEARNING; MAJOR DEPRESSION; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PROSPECTIVE STUDY; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; ENDOPHENOTYPES; FEMALE; HUMANS; MACHINE LEARNING; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PRECISION MEDICINE; PROSPECTIVE STUDIES; SERTRALINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85049356702     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291718001708     Document Type: Article

References (81)

1. American Psychiatric Association (2010) Treatment of Patients with major Depressive Disorder. 3rd Edn. Washington, DC: American Psychiatric Press.
2. Austin PC and Tu JV (2004) Bootstrap methods for developing predictive models. The American Statistician 58, 131-137.
3. Bagby RM, Quilty LC, Segal ZV, McBride CC, Kennedy SH and Costa PT (2008) Personality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy. The Canadian Journal of Psychiatry 53, 361-370.
4. Baldessarini RJ, Forte A, Selle V, Sim K, Tondo L, Undurraga J and Vázquez GH (2017) Morbidity in depressive disorders. Psychotherapy and Psychosomatics 86, 65-72.
5. Ball S, Classi P and Dennehy EB (2014) What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment. Annals of General Psychiatry 13, 8.
6. Bet PM, Hugtenburg JG, Penninx BWJH and Hoogendijk WJG (2013) Side effects of antidepressants during long-term use in a naturalistic setting. European Neuropsychopharmacology 23, 1443-1451.
7. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA and Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepres-sant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet 391, 1357-1366.
8. Cohen ZD and DeRubeis RJ (2018) Treatment selection in depression. Annual Review of Clinical Psychology 14, 209-236.
9. Cohen ZD, Kim T, Van H, Dekker J and Driessen E (2017) Recommending cognitive-behavioral versus psychodynamic therapy for mild to moderate adult depression. PsyArXiv, https://osf.io/6qxve/.
10. DeRubeis RJ, Cohen ZD, Forand NR, Fournier JC, Gelfand LA and Lorenzo-Luaces L (2014) The personalized advantage index: translating research on prediction into individualized treatment recommendations. A demonstration. PLoS ONE 9, e83875.
11. Dunner DL (2001) Acute and maintenance treatment of chronic depression. The Journal of Clinical Psychiatry 62(Suppl. 6), 10-16.
12. Eriksen BA and Eriksen CW (1974) Effects of noise letters upon the identi-fication of a target letter in a nonsearch task. Perception & Psychophysics 16, 143-149.
13. Etkin A, Patenaude B, Song YJC, Usherwood T, Rekshan W, Schatzberg AF, Rush AJ and Williams LM (2015) A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. Neuropsychopharmacology 40, 1332-1342.
14. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter A, Howland R, Warden D and Trivedi MH (2008) Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR∗D report. American Journal of Psychiatry 165, 342-351.
15. Fiedler K (2011) Voodoo correlations are everywhere-not only in neurosci-ence. Perspectives on Psychological Science 6, 163-171.
16. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC and Fawcett J (2010) Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303, 47-53.
17. Fournier JC, DeRubeis RJ, Hollon SD, Gallop R, Shelton RC and Amsterdam JD (2013) Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy. Behaviour Research and Therapy 51, 392-398.
18. Fournier JC, DeRubeis RJ, Shelton RC, Hollon SD, Amsterdam JD and Gallop R (2009) Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. Journal of Consulting and Clinical Psychology 77, 775-787.
19. Fried EI and Nesse RM (2015a) Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR∗D study. Journal of Affective Disorders 172, 96-102.
20. Fried EI and Nesse RM (2015b) Depression sum-scores don't add up: why analyzing specific depression symptoms is essential. BMC Medicine 13, 72.
21. Friedman J, Hastie T and Tibshirani R (2010) Regularization paths for gen-eralized linear models via coordinate descent. Journal of Statistical Software 33, 1-22.
22. Garge NR, Bobashev G and Eggleston B (2013) Random forest methodology for model-based recursive partitioning: the mobForest package for R. BMC Bioinformatics 14, 125.
23. Gillan CM and Whelan R (2017) What big data can do for treatment in psychiatry. Current Opinion in Behavioral Sciences 18, 34-42.
24. Goldstein BL and Klein DN (2014) A review of selected candidate endophe-notypes for depression. Clinical Psychology Review 34, 417-427.
25. Gottesman II and Gould TD (2003) The endophenotype concept in psych-iatry: etymology and strategic intentions. The American Journal of Psychiatry 160, 636-645.
26. Hamilton M (1960) A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 23, 56-62.
27. Hastie T, Tibshirani R and Friedman J (2009) The Elements of Statistical Learning: Data Mining, Inference, and Prediction, Second Edition. 2nd Edn. New York, NY: Springer.
28. Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Guzmán D, Guàrdia-Olmos J, Hinojosa-Calvo E and Herrera-Abarca JE (2009) Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. Journal of Psychiatric Research 43, 855-863.
29. Hollon SD (2016) The efficacy and acceptability of psychological interventions for depression: where we are now and where we are going. Epidemiology and Psychiatric Sciences 25, 295-300.
30. Holmes AJ, Bogdan R and Pizzagalli DA (2010) Serotonin transporter geno-type and action monitoring dysfunction: a possible substrate underlying increased vulnerability to depression. Neuropsychopharmacology 35, 1186-1197.
31. Huibers MJH, Cohen ZD, Lemmens LHJM, Arntz A, Peeters FPML, Cuijpers P and DeRubeis RJ (2015) Predicting optimal outcomes in cog-nitive therapy or interpersonal psychotherapy for depressed individuals using the personalized advantage index approach. PLoS ONE 10, e0140771.
32. Jakobsen JC, Katakam KK, Schou A, Hellmuth SG, Stallknecht SE, Leth-Møller K, Iversen M, Banke MB, Petersen IJ, Klingenberg SL, Krogh J, Ebert SE, Timm A, Lindschou J and Gluud C (2017) Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 17, 58.
33. Jakubovski E and Bloch MH (2014) Prognostic subgroups for citalopram response in the STAR∗D trial. The Journal of Clinical Psychiatry 75, 738-747.
34. Julien RM (2013) A Primer of Drug Action: A Concise Nontechnical Guide to the Actions, Uses, and Side Effects of Psychoactive Drugs, Revised and Updated. New York: Henry Holt and Company.
35. Kapelner A and Bleich J (2016) Bartmachine: machine learning with Bayesian additive regression trees. Journal of Statistical Software 70, 1-40.
36. Khan A, Dager SR, Cohen S, Avery DH, Scherzo B and Dunner DL (1991) Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology 4, 125-130.
37. Khan A, Leventhal RM, Khan SR and Brown WA (2002) Severity of depres-sion and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology 22, 40-45.
38. Khin NA, Chen Y-F, Yang Y, Yang P and Laughren TP (2011) Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US food and drug administration in support of new drug applications. The Journal of Clinical Psychiatry 72, 464-472.
39. Kirsch I (2015) Clinical trial methodology and drug-placebo differences. World Psychiatry 14, 301-302.
40. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ and Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Medicine 5, e45.
41. Kraemer HC (2013) Discovering, comparing, and combining moderators of treatment on outcome after randomized clinical trials: a parametric approach. Statistics in Medicine 32, 1964-1973.
42. Kraemer HC and Blasey CM (2004) Centring in regression analyses: a strategy to prevent errors in statistical inference. International Journal of Methods in Psychiatric Research 13, 141-151.
43. Lam RW, Kennedy SH, McIntyre RS and Khullar A (2014) Cognitive dys-function in major depressive disorder: effects on psychosocial functioning and implications for treatment. The Canadian Journal of Psychiatry 59, 649-654.
44. Leucht S, Hierl S, Kissling W, Dold M and Davis JM (2012) Putting the effi-cacy of psychiatric and general medicine medication into perspective: review of meta-analyses. The British Journal of Psychiatry 200, 97-106.
45. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y and Keefe RS (2015) A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 40, 2025-2037.
46. Marcus SC, Hassan M and Olfson M (2009) Antidepressant switching among adherent patients treated for depression. Psychiatric Services 60, 617-623.
47. Mars B, Heron J, Gunnell D, Martin RM, Thomas KH and Kessler D (2017) Prevalence and patterns of antidepressant switching amongst primary care patients in the UK. Journal of Psychopharmacology 31, 553-560.
48. McCrae RR and Costa PT (2010) NEO Inventories Professional Manual. Lutz, FL: Psychological Assessment Resources.
49. McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco AR, Craddock RC and Mayberg HS (2013) Toward a neuroima-ging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 70, 821-829.
50. McMakin DL, Olino TM, Porta G, Dietz LJ, Emslie G, Clarke G, Wagner KD, Asarnow JR, Ryan ND, Birmaher B, Shamseddeen W, Mayes T, Kennard B, Spirito A, Keller M, Lynch FL, Dickerson JF and Brent DA (2012) Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor-treatment resistant depression. Journal of the American Academy of Child and Adolescent Psychiatry 51, 404-411.
51. Milea D, Guelfucci F, Bent-Ennakhil N, Toumi M and Auray J-P (2010) Antidepressant monotherapy: a claims database analysis of treatment changes and treatment duration. Clinical Therapeutics 32, 2057-2072.
52. Moncrieff J and Kirsch I (2015) Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences. Contemporary Clinical Trials 43, 60-62.
53. Moncrieff J, Wessely S and Hardy R (2004) Active placebos versus antide-pressants for depression. The Cochrane Library.
54. NICE (2018) Depression in adults: recognition and management|guidance and guidelines|NICE.
55. Pizzagalli DA, Evins AE, Schetter EC, Frank MJ, Pajtas PE, Santesso DL and Culhane M (2008a) Single dose of a dopamine agonist impairs reinforce-ment learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacology 196, 221-232.
56. Pizzagalli DA, Goetz E, Ostacher M, Iosifescu DV and Perlis RH (2008b) Euthymic patients with bipolar disorder show decreased reward learning in a probabilistic reward task. Biological Psychiatry 64, 162-168.
57. Pizzagalli DA, Jahn AL and O'Shea JP (2005) Toward an objective character-ization of an anhedonic phenotype: a signal-detection approach. Biological Psychiatry 57, 319-327.
58. Pizzagalli DA, Webb CA, Dillon DG, Tenke CE, Kayser J, Goer F, Fava M, McGrath P, Weissman M, Parsey R, Adams P, Trombello J, Cooper C, Deldin P, Oquendo MA, McInnis MG, Carmody T, Bruder G and Trivedi MH (2018) Pretreatment rostral anterior cingulate cortex theta activity in relation to symptom improvement in depression: a randomized clinical trial. JAMA Psychiatry 75, 547-554.
59. Quilty LC, Meusel L-AC and Bagby RM (2008) Neuroticism as a mediator of treatment response to SSRIs in major depressive disorder. Journal of Affective Disorders 111, 67-73.
60. R Core Team (2013) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
61. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH and Keller MB (2003) The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry 54, 573-583.
62. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J and Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. The American Journal of Psychiatry 163, 1905-1917.
63. Saragoussi D, Chollet J, Bineau S, Chalem Y and Milea D (2012) Antidepressant switching patterns in the treatment of major depressive dis-order: a General Practice Research Database (GPRD) Study. International Journal of Clinical Practice 66, 1079-1087.
64. Schultz J and Joish V (2009) Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder. Psychiatric Services 60, 1604-1611.
65. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D and Trigwell P (1995) A scale for the assessment of hedonic tone: the Snaith-Hamilton Pleasure Scale. British Journal of Psychiatry 167, 99-103.
66. Soskin DP, Carl JR, Alpert J and Fava M (2012) Antidepressant effects on emotional temperament: toward a biobehavioral research paradigm for major depressive disorder. CNS Neuroscience & Therapeutics 18, 441-451.
67. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J and Mendlewicz J, Group for the Study of Resistant Depression (2007) Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. The Journal of Clinical Psychiatry 68, 1062-1070.
68. Stekhoven DJ and Bühlmann P (2012) Missforest-non-parametric missing value imputation for mixed-type data. Bioinformatics (Oxford, England) 28, 112-118.
69. Tang TZ, DeRubeis RJ, Hollon SD, Amsterdam J, Shelton R and Schalet B (2009) Personality change during depression treatment: a placebo-controlled trial. Archives of General Psychiatry 66, 1322-1330.
70. Thomas L, Kessler D, Campbell J, Morrison J, Peters TJ, Williams C, Lewis G and Wiles N (2013) Prevalence of treatment-resistant depression in primary care: cross-sectional data. The British Journal of General Practice 63, e852-e858.
71. Trivedi MH, McGrath PJ, Fava M, Parsey RV, Kurian BT, Phillips ML, Oquendo MA, Bruder G, Pizzagalli D, Toups M, Cooper C, Adams P, Weyandt S, Morris DW, Grannemann BD, Ogden RT, Buckner R, McInnis M, Kraemer HC, Petkova E, Carmody TJ and Weissman MM (2016) Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): rationale and design. Journal of Psychiatric Research 78, 11-23.
72. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK and Fava M (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. American Journal of Psychiatry 163, 28-40.
73. Turner EH, Matthews AM, Linardatos E, Tell RA and Rosenthal R (2008) Selective publication of antidepressant trials and Its influence on apparent efficacy. New England Journal of Medicine 358, 252-260.
74. Uher R, Perlis RH, Henigsberg N, Zobel A, Rietschel M, Mors O, Hauser J, Dernovsek MZ, Souery D, Bajs M, Maier W, Aitchison KJ, Farmer A and McGuffin P (2012a) Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychological Medicine 42, 967-980.
75. Uher R, Tansey KE, Malki K and Perlis RH (2012b) Biomarkers predicting treatment outcome in depression: what is clinically significant? Pharmacogenomics 13, 233-240.
76. Vrieze E, Pizzagalli DA, Demyttenaere K, Hompes T, Sienaert P, de Boer P, Schmidt M and Claes S (2013) Reduced reward learning predicts outcome in major depressive disorder. Biological Psychiatry 73, 639-645.
77. Vuorilehto MS, Melartin TK and Isometsä ET (2009) Course and outcome of depressive disorders in primary care: a prospective 18-month study. Psychological Medicine 39, 1697-1707.
78. Wakefield JC and Schmitz MF (2013) When does depression become a dis-order? Using recurrence rates to evaluate the validity of proposed changes in major depression diagnostic thresholds. World Psychiatry 12, 44-52.
79. Waljee AK, Mukherjee A, Singal AG, Zhang Y, Warren J, Balis U, Marrero J, Zhu J and Higgins PD (2013) Comparison of imputation methods for missing laboratory data in medicine. BMJ Open 3, e002847.
80. Watson D, Clark LA, Weber K, Assenheimer JS, Strauss ME and McCormick RA (1995) Testing a tripartite model: II. Exploring the symptom structure of anxiety and depression in student, adult, and patient samples. Journal of Abnormal Psychology 104, 15-25.
81. Webb CA, Dillon DG, Pechtel P, Goer FK, Murray L, Huys QJ, Fava M, McGrath PJ, Weissman M, Parsey R, Kurian BT, Adams P, Weyandt S, Trombello JM, Grannemann B, Cooper CM, Deldin P, Tenke C, Trivedi M, Bruder G and Pizzagalli DA (2016) Neural correlates of three promising endophenotypes of depression: evidence from the EMBARC study. Neuropsychopharmacology 41, 454-463.